Versant Capital Management, Inc Astria Therapeutics, Inc. Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 298 shares of ATXS stock, worth $1,811. This represents 0.0% of its overall portfolio holdings.
Number of Shares
298Holding current value
$1,811% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ATXS
# of Institutions
118Shares Held
51.1MCall Options Held
5.3KPut Options Held
6.1K-
Perceptive Advisors LLC New York, NY6.49MShares$39.4 Million1.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$31 Million0.57% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$25.4 Million1.59% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.82MShares$23.2 Million4.93% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$21.6 Million6.47% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $92.3M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...